Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $689.4 million.

  • Abivax's Cash & Equivalents rose 14916.01% to $689.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $689.4 million, marking a year-over-year increase of 14916.01%. This contributed to the annual value of $154.1 million for FY2024, which is 4345.07% down from last year.
  • According to the latest figures from Q3 2025, Abivax's Cash & Equivalents is $689.4 million, which was up 14916.01% from $69.0 million recorded in Q2 2025.
  • Over the past 5 years, Abivax's Cash & Equivalents peaked at $689.4 million during Q3 2025, and registered a low of $27.5 million during Q4 2022.
  • In the last 5 years, Abivax's Cash & Equivalents had a median value of $212.6 million in 2023 and averaged $225.4 million.
  • As far as peak fluctuations go, Abivax's Cash & Equivalents surged by 88588.07% in 2023, and later plummeted by 7457.24% in 2025.
  • Abivax's Cash & Equivalents (Quarter) stood at $69.4 million in 2021, then crashed by 60.4% to $27.5 million in 2022, then soared by 885.88% to $271.1 million in 2023, then crashed by 43.15% to $154.1 million in 2024, then surged by 347.33% to $689.4 million in 2025.
  • Its Cash & Equivalents stands at $689.4 million for Q3 2025, versus $69.0 million for Q2 2025 and $151.7 million for Q1 2025.